{"id":"NCT04784091","sponsor":"Tarsus Pharmaceuticals, Inc.","briefTitle":"Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","officialTitle":"Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-29","primaryCompletion":"2022-05-09","completion":"2022-05-09","firstPosted":"2021-03-05","resultsPosted":"2023-12-21","lastUpdate":"2023-12-21"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Blepharitis"],"interventions":[{"type":"DRUG","name":"TP-03","otherNames":[]},{"type":"DRUG","name":"TP-03 Vehicle","otherNames":[]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Control","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.","primaryOutcome":{"measure":"The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.","timeFrame":"43 days","effectByArm":[{"arm":"Active","deltaMin":0.547,"sd":0.035},{"arm":"Control","deltaMin":0.122,"sd":0.023}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["37285925"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":203},"commonTop":["Instillation site pain","Visual acuity reduced","Dry eye","Punctate keratitis","Hordeolum"]}}